Safety and Effectiveness of Magnetic Peripheral Nerve Stimulation for the Treatment of Chemotherapy Induced Neuropathy

NCT05935956 | Completed FDA Device

• 1 other identifier: NLM-005
• Study Type: observational
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

Assess the safety and effectiveness of Axon Therapy in the treatment of chemotherapy-induced neuropathy

Conditions

Neuralgia; Neuropathic Pain; Chemotherapy-induced Peripheral Neuropathy

Keywords

Transcutaneous Magnetic Peripheral Nerve Stimulation; Axon Therapy; Peripheral Neuropathy; Chemotherapy-induced Peripheral Neuropathy

Outcome Measures

Primary Outcomes (2)

• Effectiveness of mPNS for treating chemotherapy-induced neuropathy, measured by a reduction in pain at Day 90 as compared to Baseline, using a visual analog scale (VAS).

  The primary effectiveness endpoint is to demonstrate a reduction in pain at Day 90 as compared to Baseline where pain is measured in-clinic using a visual analog scale (VAS). Scores on the VAS range from 0 (no pain) to 10 (worst possible pain).

  90 days

• Safety of mPNS for the treatment of chemotherapy-induced neuropathy, as measured by the incidence of therapy-related adverse events (AEs) through Day 90.

  The primary safety endpoint is the occurrence of therapy-related adverse events (AEs) through Day 90.

  90 days

Secondary Outcomes (6)

• Patient Reported Outcome (PRO) assessment via the Pain Disability Index (PDI), which measures the degree that chronic pain interferes with normal role functioning.

  Baseline and 90 days

• PRO assessment via the EuroQol Group Quality of Life Questionnaire (EQ-5D-3L), which measures the impact that chronic pain has on 5 aspects of a subject's quality of life.

  Baseline and 90 days

• PRO assessment via the Daily Sleep Interference Scale (DSIS), which measures how much a subject's pain interferes with that subject's sleep.

  Baseline and 90 days

• PRO assessment via the Depression Anxiety Stress Scales (DASS), which measures the level of depression, anxiety and stress a subject is experiencing.

  Baseline and 90 days

• PRO assessment via the Brief Pain Inventory (BPI-SF) to assess the severity of pain and the impact of pain on daily functions.

  Baseline and 90 days

Interventions

Magnetic Peripheral Nerve Stimulation DEVICE

Magnetic Peripheral Nerve Stimulation

Also known as: Axon Therapy

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Approximately twenty (20) subjects aged 18-85 years old and presenting with chemotherapy induced neuropathy will be enrolled at 1 site in the United States.

You may qualify if:

• Evidence of a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the study.
• Subject is willing and able to comply with scheduled visits, treatment plan, daily pain, and other study procedures subject is able and willing to complete twice daily diary for 90 days.
• Subject must be literate in English to fill out the study questionnaires.
• Men or women of any race or ethnicity who are 18-85 years of age.
• Subject must have chemotherapy induced neuropathy for more than three months per medical history.
• Subject has a pain score \>5 on a VAS at Enrollment/Screening Visit.
• Subject has completed at least one of the two daily pain diary entries on at least three days between the Enrollment/Screening Visit and Visit 1 with a mean pain score of ≥4 and \<10 based on Daily VAS to be eligible for the study.
• Subject has been on a stable pain medication regimen for at least 28 days, as determined by the investigator or is not taking pain medications, at the baseline assessment in this study.

You may not qualify if:

• Subjects with neuropathic pain due to post-herpetic neuropathy, HIV, trigeminal neuralgia, carpal or tarsal tunnel syndrome; subjects whose post-traumatic neuropathic pain is categorized as central (e.g., spinal cord injury) rather than peripheral.
• Subject has a currently diagnosed progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, or severe/critical spinal stenosis (stenosis).
• Subjects with skin conditions in the affected dermatome that in the judgment of the investigator could interfere with evaluation of the neuropathic pain condition.
• Subjects with other pain that may confound assessment or self-evaluation of the peripheral neuropathic pain.
• Participation in any other clinical trial within 30 days prior to screening and/or during participation in this study.
• Any subject considered at risk of suicide or self-harm based on investigator judgment and/or the details of a risk assessment.
• Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormality, or other factors that may increase the risk associated with study participation or investigational product administration or may interfere with compliance or the interpretation of study results and, in the judgment of the investigator would make the subject inappropriate to participate in the study.
• Subjects with pending Worker's Compensation, civil litigation, or disability claims; Subjects with fully resolved litigation and compensation claims can participate.
• Phantom limb pain or pain that feels like it is coming from a body part that is no longer there.
• Subjects with shrapnel or ferromagnetic objects
• Subject is currently taking a morphine equivalent daily dose \> 120 mg/day.
• Subject is currently pregnant or is a woman of childbearing potential, not using adequate contraception or not willing to comply with contraception for the duration of the study.
• Subjects with active drug or alcohol abuse within 1 year prior to screening.

Sponsors & Collaborators

• NeuraLace Medical, Inc.: lead

Study Sites (1)

Carolinas Pain Institute and Center for Clinical Research

Winston-Salem, North Carolina, 27103, United States

Location

MeSH Terms

Conditions

Neuralgia; Peripheral Nervous System Diseases

Condition Hierarchy (Ancestors)

Neuromuscular Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Carrie Johnson, MD, PhD

  Carolinas Pain Institute and Center for Clinical Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 12, 2023
• First Posted: July 7, 2023
• Study Start: June 9, 2023
• Primary Completion: December 21, 2023
• Study Completion: December 21, 2023
• Last Updated: July 11, 2024

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)